Patents Assigned to GLADIUS PHARMACEUTICALS CORPORATION
  • Patent number: 11028103
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 8, 2021
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry D. Sutton, Sophia Yu
  • Patent number: 10239890
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 26, 2019
    Assignee: Gladius Pharmaceuticals Corporation
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 10000509
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 19, 2018
    Assignee: Gladius Pharmaceuticals Corporation
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9975905
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 22, 2018
    Assignee: Gladius Pharmaceuticals Corporation
    Inventors: Larry D. Sutton, Sophia Yu
  • Patent number: 9862729
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 9, 2018
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9809605
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 7, 2017
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9453032
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: September 27, 2016
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry Sutton, Sophia Yu